GlassScriptPhysician profile
Justin Sevy
NPI 1194106898
$2,594.83
in general payments reported to CMS, 2019-2025
30 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $229 · 2023: $578 · 2024: $748 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $756.39 | 2022-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $303.30 | 2022-2025 | Krystexxa, Prolia, Evenity |
| Lilly USA, LLC | $208.94 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $196.02 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $137.42 | 2023-2025 | Airsupra, Farxiga, Flumist Quadrivalent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.02 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $109.65 | 2023-2025 | Shingrix, Arexvy |
| Boston Scientific Corporation | $92.88 | 2022-2025 | General - Pain Management |
| Organon LLC | $62.63 | 2024-2025 | Nexplanon |
| Janssen Pharmaceuticals, INC | $56.47 | 2023-2024 | Spravato |
| Sanofi Pasteur INC. | $55.55 | 2023-2025 | |
| Horizon Therapeutics Plc | $53.01 | 2023 | Krystexxa |
| Lucid Diagnostics INC. | $44.73 | 2023 | |
| Sumitomo Pharma America, INC. | $42.45 | 2024 | Gemtesa |
| Rgh Enterprises LLC | $42.00 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $40.49 | 2022 | |
| Exact Sciences Corporation | $29.38 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $28.16 | 2023 | Sunosi |
| Sanofi-Aventis U.S. LLC | $24.86 | 2024 | |
| Nevro Corp. | $22.38 | 2022 | |
| Aimmune Therapeutics, INC. | $21.70 | 2024 | |
| Phathom Pharmaceuticals, INC. | $20.25 | 2024 | Voquezna |
| Harmony Biosciences LLC | $18.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.58 | 2023 | |
| Becton, Dickinson and Company | $15.52 | 2022 | |
| Dexcom, INC. | $15.40 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $15.15 | 2025 | Ozempic, Rybelsus |
| Ultragenyx Pharmaceutical INC. | $14.92 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.31 | 2023 | Quviviq |
| Optinose US, INC. | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Sevy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.